Download
Pharmaceutical Enterprise
Magnesium sulfate powder
Instruction
Sertificates
Attention
Contraindications
Severe chronic renal failure, hypersensitivity to magnesium sulfate, appendicitis, rectal bleeding (including undiagnosed), intestinal obstruction. acute inflammatory diseases of the gastrointestinal tract, dehydration, hypermanemia, pregnancy, breastfeeding, children under 18 years of age.
Magnesium sulfate powder
It has a choleretic reflex effect, is an antidote for poisoning with salts of heavy metals and, due to its laxative effect, removes them from the body.
Registration number: ЛП-008402
Trade name of the drug : Magnesium sulfate
International nonproprietary name : magnesium sulfate
Dosage form : powder for oral solution
Composition for 1 package
Active ingredient: magnesium sulfate heptahydrate 10 g, 20 g or 25 g
Description
White or almost white crystalline powder or colorless prismatic crystals
Description of the prepared solution
When the contents of 1 packet are dissolved in 200 ml of water at room temperature, a clear, colorless solution is obtained.
Pharmacotherapeutic group : laxative
ATX code : A06AD04
Pharmacological properties
Pharmacodynamics
When taken orally, it has a choleretic (reflex effect on the receptors of the duodenal mucosa) and a laxative effect (due to poor absorption of the drug in the intestine, high osmotic pressure is created in it, water accumulates in the intestine, the intestinal contents are liquefied, and peristalsis is enhanced). It is an antidote for poisoning with salts of heavy metals, forms insoluble sulfate complexes of heavy metals and, due to its laxative effect, removes them from the body
Pharmacokinetics
When taken orally, it is poorly absorbed (no more than 20%) in the jejunum and ileum, and is reabsorbed from bile, pancreatic and intestinal juice. With malabsorption syndrome and consumption of foods rich in fat, the absorption of magnesium ions is reduced. Connection with intracellular proteins and macroermic phosphates - 30%.
Time of onset of maximum plasma concentration. blood - 4 hours. Magnesium ions are deposited in bones, skeletal muscles, kidneys, liver and myocardium; in small quantities in tissue fluid and red blood cells. Penetrates through the blood-brain and placental barrier, creating concentrations in breast milk that are twice as high as those in plasma. Excretion is carried out by the kidneys and through the intestines.
Indications for use
Constipation. Cleansing the intestines before diagnostic procedures. Poisoning with salts of heavy metals (mercury, arsenic, tetraethyl lead, barium).
Contraindications
Severe chronic renal failure, hypersensitivity to magnesium sulfate, appendicitis, rectal bleeding (including undiagnosed), intestinal obstruction, acute inflammatory diseases of the gastrointestinal tract, dehydration, hypermagnesemia, pregnancy, breastfeeding, children under 18 years.
Carefully
Cardiac conduction disturbances, heart failure, chronic renal failure.
Use during pregnancy and breastfeeding
Magnesium sulfate is contraindicated during pregnancy and breastfeeding. If it is necessary to use the drug during lactation, breastfeeding should be discontinued.
Directions for use and doses
Taken orally.
Adults - 20-25 r once a day on an empty stomach, after dissolving the drug in a glass of water (200 ml).
It is possible to use the drug in the form of enemas (50-100 ml of 20-30% solution).
In case of poisoning with heavy metal salts, wash the stomach with a 1% solution of magnesium sulfate or give 20 g orally, dissolved in a glass of water (200 ml).
To lavage the stomach, the patient is given a 1% solution of magnesium sulfate to drink (20 g per 2 liters of water). If vomiting does not occur quickly, then it is caused by mechanical action on the root of the tongue.
Washing is carried out until the wash water is clear.
Side effects
Nausea, vomiting, diarrhea, exacerbation of inflammatory diseases of the gastrointestinal tract, flatulence, spastic abdominal pain, thirst, electrolyte imbalance (fatigue, asthenia, confusion, arrhythmia, convulsions), hypermagnesemia in the presence of renal failure (early signs of hypermagnesemia : bradycardia, diplopia, sudden “rush” of blood to the skin of the face, headache, dizziness, decreased blood pressure, nausea, shortness of breath, slurred speech, vomiting, weakness).
If the above adverse reactions or adverse reactions not listed in these instructions for medical use of the drug occur, you should consult a doctor.
Overdose
Symptoms: severe diarrhea. If you suspect an overdose, you should consult a doctor!
Treatment: symptomatic. As an antidote, calcium preparations (calcium chloride and calcium gluconate), peritoneal dialysis or hemodialysis, and symptomatic agents (corrective functions of the central nervous system and cardiovascular system) are administered intravenously (slowly).
Interaction with other drugs
Reduces the effect of oral anticoagulants (including coumarin derivatives or indanedione derivatives), cardiac glycosides, phenothiazines (especially chlorpromazine). Reduces the absorption of ciprofloxacin, etidronic acid, tetracycline antibiotics (forms non-absorbable complexes with oral tetracyclines), weakens the effect of streptomycin and tobramycin (laxatives containing magnesium should be taken 1-2 hours after using the above medications). Pharmaceutically incompatible (precipitate is formed) with calcium preparations, ethanol (in high concentrations), carbonates, bicarbonates and phosphates of alkali metals, salts of arsenic acid, barium, strontium, clindamycin, hydrocortisone, polymyxin B, procaine, salicylates and tartrates.
special instructions
The drug should be taken occasionally (not regularly, if situations specified in the “Indications for Use” section arise); systematic use is not recommended. If there is no bowel movement after taking the medicine, you should consult a doctor!
If you have heart or kidney failure, an eating disorder (anorexia and bulimia), or if you take laxatives for a week, you should consult your doctor!
Impact on the ability to drive vehicles and machinery
During the treatment period, patients should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions (risk of developing diplopia, dizziness, headache).
Release form
Powder for the preparation of solution for oral administration.
10, 20 or 25 g in heat-sealable bags made of a combined material (consisting of paper, polyethylene, aluminum foil and polyethylene).
1, 2, 3, 4, 5, 10, 12, 15, 20, 30, 40, 50 packages along with instructions for medical use are placed in a cardboard pack.
Best before date
3 years. Do not use after the expiration date.
Storage conditions
Store at a temperature not exceeding 25°C.
Keep out of the reach of children.
Vacation conditions
Available without a prescription.
